Xavier Becerra, President-elect Joe Biden’s nominee for HHS secretary, recently asked the federal government to use a controversial monopoly-busting mechanism to lower the cost of the COVID-19 drug remdesivir, and there are several COVID-19 drugs and vaccines that are susceptible to the government’s so-called march-in rights. The Trump administration did not use the march-in policy, but both Democratic and Republican attorneys general AGs as well as left-leaning policy experts want the Biden administration to consider it. Becerra’s position on remdesivir...